• Santarus Inc., of San Diego, said based on data from its Phase I study testing SAN-300, an antibody designed to inhibit very late antigen-1, the firm will initiate a placebo-controlled, multiple-ascending-dose Phase IIa trial with subcutaneous administration in patients with active rheumatoid arthritis. The study is slated to start this quarter.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter